Rationale: DPP-4 (dipeptidyl peptidase-4) inhibitors have increased the risk of heart failure events in both randomized clinical trials and observational studies, but the mechanisms that underlie their deleterious effect remain to be elucidated. Previous work has implicated a role of these drugs to promote cardiac fibrosis.
Evidence That DPP-4 Inhibitors Increase the
Risk of Heart Failure DPP-4 (dipeptidyl peptidase-4) inhibitors are popular choices for the management of type 2 diabetes mellitus because of their tolerability and ability to reliably lower blood glucose with oral administration. However, the use of DPP-4 inhibitors can lead to worsening heart failure in patients with established cardiovascular disease or metabolic abnormalities. 1 The US Food and Drug Administration has issued a warning about an increased risk of serious heart failure events for both saxagliptin and alogliptin. 2 In the SAVOR-TIMI53 trial (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53), patients treated with saxagliptin experienced an increased risk of hospitalization for heart failure. 3 In the EXAMINE trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care), patients without a history of heart failure were hospitalized for heart failure more frequently when treated with alogliptin, as compared with placebo. 4 Additionally, in the VIVIDD trial (Vildagliptin in Ventricular Dysfunction Diabetes) of patients with both diabetes mellitus and left ventricular systolic dysfunction, vildagliptin lead to adverse effects on cardiac remodeling and a higher risk of cardiovascular hospitalization and death. 5 A pooled analysis suggested increased adverse heart failure events with linagliptin. 6 A large-scale trial with omarigliptin did not note an increased risk of heart failure, but risk estimates were unreliable because of the small number of events. 1, 7 Although a largescale trial with sitagliptin did not report an increased risk of heart failure hospitalizations, the estimates of risk may have been influenced by a high prevalence of metformin use and a low and declining use of insulin as background treatments. 1 Worsening heart failure with all DPP-4 inhibitors has been reported in several meta-analyses and observational studies. [8] [9] [10] Furthermore, adverse heart failure events have been
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disproportionately reported among users of DPP-4 inhibitors in clinical practice; 11 clinical deterioration may be particularly apparent after the initiation of treatment. 12 The weight of evidence is consistent with a class effect of these drugs. 
Mechanisms by Which DPP-4 Inhibitors Could
Lead to Heart Failure Certain antihyperglycemic drugs lead to worsening heart failure because they promote sodium retention. However, DPP-4 inhibitors block sodium reabsorption in the renal tubules, and thus, their effects of the kidney cannot explain the increased risk of heart failure.
13
Effects of DPP-4 Inhibitors on the Heart
Could DPP-4 inhibitors lead to heart failure by exerting a deleterious effect on the heart? In experimental models, DPP-4 inhibition has been accompanied by increases in myocardial cAMP, which is related to potentiation of endogenous GLP-1 (glucagon-like peptide-1). 14, 15 Although sustained increases in cAMP may exacerbate the clinical course of heart failure, 16 the increase produced by modest GLP-1 receptor signaling might be confined to intracellular microdomains that are not linked to pathways that cause deleterious effects on cardiomyocytes. [17] [18] [19] [20] Such compartmentation may help to explain why DPP-4 inhibitors do not increase in heart rate, unlike long-acting GLP-1 analogs. 21 However, GLP-1 is not the only substrate for DPP-4, and many of the actions of DPP-4 inhibitors are related to their potentiation of other endogenous peptides that have important effects on the cardiovascular system. Specifically, DPP-4 acts to degrade SDF-1 (stromal cell-derived factor 1)-a stem cell chemokine that acts via CXCR4 (C-X-C chemokine receptor) and CXCR7 receptors. 22 In addition, by acting as a converting enzyme, DPP-4 modulates the cardiovascular responses to NPY (neuropeptide Y), thereby shifting its activities away from the NPY-Y1 (neuropeptide Y-Y1) receptor. 23 Finally, DPP-4 can degrade substance P-a tachykinin neuropeptide that signals through the NK1 (neurokinin 1) receptor. 24 Therefore, DPP-4 inhibition potentiates the actions of endogenous SDF-1, NPY, and substance P, which can adversely affect both cardiac structure and function. Circulating levels of these peptides are characteristically increased in patients with heart failure. [25] [26] [27] Could potentiation of SDF-1, NPY, and substance P underlie the effect of DPP-4 inhibitors to increase the risk of heart failure? Heart failure in patients with diabetes mellitus can present with a preserved ejection fraction or a reduced ejection fraction. 28 Patients with impaired systolic function primarily have a disorder that is characterized by cardiomyocyte loss and stretch, whereas those with values for ejection fraction in the normal range typically have evidence of a systemic inflammatory state that leads to cardiac fibrosis and decreased ventricular distensibility. 28 Could the actions of DPP-4 inhibitors increase the likelihood of both phenotypes of heart failure that are seen in type 2 diabetes mellitus?
Effects of DPP-4 Inhibitors on Cardiac Inflammation and Fibrosis
Diabetes mellitus is characterized by increased epicardial fat, 29 and inflammation of adipose tissue can be exacerbated by both GLP-1 and CXCR4 receptor signaling. [30] [31] [32] An inflammatory state in epicardial adipose tissue can be readily transmitted to the underlying myocardium. 33 Such a mechanism may explain why potentiation of SDF-1 leads to myocardial fibrosis 34 and why cardiac fibrosis is enhanced by DPP-4 inhibition but prevented by CXCR4 antagonism. 35, 36 Interestingly, potentiation of the actions of substance P and NPY by DPP-4 inhibition can also promote profibrotic pathways in the myocardium. 23, 37 However, the effects of DPP-4 inhibitors in patients with a known diagnosis of heart failure with a preserved ejection fraction have not been formally investigated, and conceivably, an effect of fibrosis to exacerbate the clinical course of these patients might require prolonged periods of therapy. Yet, in both randomized clinical trials and observational studies, the increased risk of heart failure events with DPP-4 inhibitors was seen early after initiation of treatment. 10, 19 Furthermore, the adverse effects on cardiac remodeling seen with vildagliptin were observed in patients with heart failure and a
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Novelty and Significance
What Is Known?
• DPP-4 (dipeptidyl peptidase-4) inhibitors are commonly prescribed for the treatment of patients with type 2 diabetes mellitus.
• The major concern with the use of these drugs has been their effect to increase the risk of serious heart failure events.
• Previous studies have suggested that this deleterious effect could result from an action of these drugs to promote cardiac fibrosis.
What New Information Does This Article Contribute?
• DPP-4 inhibitors augment the effects of many endogenous peptides that are capable of stimulating the sympathetic nervous system.
• The use of these drugs has been shown to cause stimulation of the sympathetic nervous system, which can cause deleterious effects on the structure and function of the heart muscle.
The use of DPP-4 inhibitors has been shown to increase the risk of heart failure events in both randomized clinical trials and observational studies. The importance of this deleterious action is highlighted by the fact that the risk of worsening heart failure events with DPP-4 inhibitors is diminished when the effects of the sympathetic nervous system are blocked by the use of β-adrenergic receptor blocking drugs. This information is important because DPP-4 inhibitors (but not β-blockers) are widely used in patients with type 2 diabetes mellitus.
reduced ejection fraction. 12 This disorder is characterized primarily by a loss of cardiomyocytes rather than inflammation and fibrosis in the myocardium.
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Effects of DPP-4 Inhibitors on Cardiomyocyte Viability and Death
The sympathetic nervous system contributes importantly to the progression of heart failure in patients who have impaired systolic function, accounting for the benefits of long-term β-blockade in these individuals. Interestingly, in experimental heart failure, potentiation of the effects of endogenous SDF-1 acts on the central nervous system to cause a striking increase in sympathetic outflow. 38, 39 Both NPY and substance P (which are coreleased with norepinephrine from nerve terminals) can further increase sympathetic nerve activity, particularly in the periphery. 24, 40, 41 As a result of these potentiating effects, DPP-4 inhibition predictably leads to an increase in the outflow of impulses to peripheral sympathetic nerves and the release of norepinephrine in both experimental and clinical studies, particularly in patients with diabetes mellitus, especially when they are receiving drugs that block the renin-angiotensin system. [42] [43] [44] [45] What are the consequences of the sympathetic overactivity produced by DPP-4 inhibition? Prolonged agonism of β-adrenergic receptors can aggravate heart failure through 2 potential mechanisms. 46 On one hand, β-receptor stimulation can lead to increases in cAMP, signaling through protein kinase A and cardiotoxicity. 47, 48 However, this response seems to be attenuated by SDF-1, possibly because the chemokine acts (through a G i protein-coupled mechanism) to inhibit the cAMP response to β-receptor stimulation. 49, 50 Interference with cAMP signaling may explain the action of DPP-4 inhibition to attenuate adrenergically mediated hypertrophy and arrhythmias and may contribute to the lack of a positive chronotropic response to DPP-4 inhibitors in clinical trials. 51, 52 On the other hand, β-receptor stimulation also leads to increased signaling through CaMKII (Ca++/calmodulin-dependent protein kinase II), which may be the primary mechanism by which sympathetic overactivity causes calcium overload, cardiomyocyte apoptosis, and adverse cardiac remodeling. 46, [53] [54] [55] Interestingly, this effect on CaMKII does not seem to be attenuated by SDF-1; in fact, potentiation of SDF-1 and other peptides by DPP-4 inhibitors is likely to increase the activity of CaMKII because of an increased sympathetic nerve traffic. [38] [39] [40] [41] This may explain why experimental suppression of SDF-1 and CXCR7 acts to attenuate the response to β-adrenergic receptor stimulation and ameliorate adverse cardiac remodeling after myocardial infarction; 22, 56 additionally, high levels of SDF-1 may act directly to cause apoptosis in the myocardium. 57 These deleterious actions could be further augmented by an effect of DPP-4 inhibitors to potentiate NPY and substance P. Stimulation of the NPY-Y1 receptor leads to detrimental effects on the structure and function of cardiomyocytes, 58 and potentiation of substance P can also accelerate cardiomyocyte apoptosis.
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Interaction of DPP-4 Inhibitors and β-Blockers in the SAVOR-TIMI53 Trial
The possibility that DPP-4 inhibitors can contribute to the evolution of heart failure by sympathetic activation is supported by the findings in a large-scale clinical trial. In SAVOR-TIMI53, an increased risk of hospitalizations for heart failure was observed in patients who were treated with saxagliptin, but the magnitude of this effect was meaningfully attenuated in patients who were concomitantly treated with β-blockers. Saxagliptin increased the risk of heart failure by 81% in the 6330 patients not receiving β-blockers (hazard ratio, 1.81 [1.21-2.76]) but by only 18% in the 10 162 patients who were treated with β-blockers (hazard ratio, 1.18 [0.97-1.43]). The latter effect was not significant, despite a greater degree of statistical power; the interaction P value for the influence of β-blockers on the risk of saxagliptin was 0.06.
Summary and Conclusions
The use of DPP-4 inhibitors in type 2 diabetes mellitus is accompanied by an increased risk of heart failure, which seems to be a class effect of these drugs, although the magnitude of risk may be influenced by concurrent therapy. 1 Many mechanisms could contribute to this deleterious effect, including activation of the sympathetic nervous system to stimulate β-receptor signaling and cause cardiomyocyte cell death. Inhibition of DPP-4 potentiates the actions of SDF-1, NPY, and substance P to increase sympathetic nerve traffic and (through β-receptor stimulation) could cause cardiomyocyte injury and loss (through a CaMKII mechanism). This framework could explain why β-blockers seemed to have attenuated the risk of heart failure with DPP-4 inhibition in a large-scale trial. The proposed hypothesis warrants further study, and if confirmed, the postulated mechanisms have important implications for patient care. In patients with type 2 diabetes mellitus, DPP-4 inhibitors are popular, but β-blockers are underutilized because of fears of masking hypoglycemia.
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